The goal of Fervent Pharmaceuticals is to develop a treatment that improves women’s health and their quality of life. Our lead compound FP-101 is a non-hormonal/non-herbal/non-antidepressant product for the treatment of vasomotor symptoms associated with menopause and hot flashes. This indication represents an unmet medical need in a substantial and motivated market.
With approximately 115 million women worldwide transitioning through menopause and experiencing hot flashes, night sweats and associated insomnia, conservative annual estimates of the worldwide market extend to $8 billion.
Utilizing the FDA’s 505b(2) application process, Fervent’s strategy is to develop an enhanced formulation of a proven, well-characterized pharmaceutical product that already addresses other substantial patient populations. Such re-purposing can assist patients to experience therapeutic efficacy with fewer side effects and more convenient dosing, while keeping costs of development lower and shortening the time required to bring beneficial therapies to market.
To help reach our goals, we’ve joined forces with a select group of partners that will help make our products a reality. To find out more, please visit our Development Partners page.
